Novel Crystalline Form of Enavogliflozin and Preparation Method
Summary
The USPTO published patent application US20260098033A1 for a novel crystalline form of enavogliflozin, an SGLT2 inhibitor for diabetes treatment. The new form exhibits improved thermodynamic stability, reduced hygroscopicity, enhanced long-term storage characteristics, and faster drug absorption compared to prior known forms. The application includes the preparation method and covers pharmaceutical compositions containing the crystalline form.
What changed
The USPTO published patent application US20260098033A1 covering a novel crystalline form of enavogliflozin (a diabetes drug, SGLT2 inhibitor class) and its preparation method. The application claims superior thermodynamic stability and reduced hygroscopicity compared to previously reported crystalline forms, providing improved long-term storage and pharmaceutical stability. The new form also demonstrates a shorter time to reach Cmax, enabling faster therapeutic effect onset.
Pharmaceutical companies developing or marketing SGLT2 inhibitor drugs should monitor this application's prosecution and resulting claims. Drug developers and investors in the diabetes therapeutic space should consider the IP implications for future formulations and generic entry strategies. The claimed improvements in stability and absorption rate could represent a competitive differentiation if the patent issues.
What to do next
- Monitor the patent prosecution status and any issued claims
- Assess the IP landscape for SGLT2 inhibitor drug development
- Review preparation method for potential licensing or research applications
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NOVEL CRYSTALLINE FORM OF ENAVOGLIFLOZIN, AND PREPARATION METHOD THEREFOR
Application US20260098033A1 Kind: A1 Apr 09, 2026
Inventors
Youn Jung Yoon, Hee Kyoon Yoon, Ji Soo Choi, Hye Young Ji, Hyun Woo Lim
Abstract
The present invention relates to a novel crystalline form of enavogliflozin, and a preparation method therefor. The novel crystalline form of enavogliflozin, according to the present invention, has thermodynamic stability and a hygroscopic property that are superior to those of a conventionally reported crystalline form of enavogliflozin, and thus has excellent long-term storage and pharmaceutical stability. In addition, the time to reach Cmax is shorter than that of the conventionally reported crystalline form of enavogliflozin such that drug effects can be rapidly exhibited, and thus the present invention can be effectively used.
CPC Classifications
C07D 407/04 A61K 31/351
Filing Date
2023-09-27
Application No.
19115817
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.